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S UMMA R Y
S E T T I NG : Xpertw MTB/RIF is the most widely used
molecular assay for rapid diagnosis of tuberculosis (TB).
The number of polymerase chain reaction cycles after
which detectable product is generated (cycle threshold
value, CT) correlates with the bacillary burden.
OB J E C T I V E : To investigate the association between
Xpert CT values and smear status through a systematic
review and individual-level data meta-analysis.
DE S I GN : Studies on the association between CT values
and smear status were included in a descriptive systematic
review. Authors of studies including smear, culture and
Xpert results were asked for individual-level data, and
receiver operating characteristic curves were calculated.
R E SU LT S : Of 918 citations, 10 were included in the
descriptive systematic review. Fifteen data sets from
studies potentially relevant for individual-level data
meta-analysis provided individual-level data (7511
samples from 4447 patients); 1212 patients had positive
Xpert results for at least one respiratory sample (1859
samples overall). ROC analysis revealed an area under
the curve (AUC) of 0.85 (95%CI 0.82–0.87). Cut-off CT
values of 27.7 and 31.8 yielded sensitivities of 85%
(95%CI 83–87) and 95% (95%CI 94–96) and specific-
ities of 67% (95%CI 66–77) and 35% (95%CI 30–41)
for smear-positive samples.
CONC LU S I ON : Xpert CT values and smear status were
strongly associated. However, diagnostic accuracy at set
cut-off CT values of 27.7 or 31.8 would not replace smear
microscopy. How CT values compare with smear micros-
copy in predicting infectiousness remains to be seen.
K E Y WO RD S : systematic review; diagnosis; Xpert;
cycle threshold value
THE XPERTw MTB/RIF (Cepheid, Sunnyvale, CA,
USA) assay is an automated real-time molecular assay
for rapid diagnosis of tuberculosis (TB) and detection
of rifampicin resistance, recommended for use as the
initial diagnostic test in individuals with suspected
multidrug-resistant TB (MDR-TB) or human immu-
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nodeficiency virus associated TB.1 Xpert was first
endorsed by the World Health Organization (WHO)
in December 2010. In 2013, the WHO recommended
that Xpert be used as the initial diagnostic test for all
adults and children with signs and symptoms of TB,
rather than microscopy and culture.1,2 A recently
updated Cochrane review estimated pooled Xpert
sensitivity to be 89% (95% confidence interval [CI]
85–92) and pooled specificity to be 99% (95%CI 98–
99).3 Xpert, which has a lower biohazard risk4 and is
less operator-dependent than conventional smear
microscopy, is undergoing a major global roll-out in
a number of high-burden countries, and has already
replaced smear microscopy in South Africa.5
The Xpert assay uses molecular beacon technology
to detect DNA sequences amplified in a hemi-nested
real-time polymerase chain reaction (PCR) assay. The
analytical limit of detection of Xpert, defined as the
minimum number of bacilli that can be detected with
95% confidence, is 131 (95%CI 106–176) colony
forming units per ml of clinical sputum sample.6,7
Xpert thus has a limit of detection that is 50–100
times greater than that of smear microscopy, and is
half as sensitive as liquid culture.8,9 The assay’s cycle
threshold value (CT), which is the number of PCR
cycles after which each of the five probes is
considered positive, provides a semiquantitative
measure of bacillary burden in sputum.6,10 Myco-
bacterium tuberculosis bacillary load therefore cor-
relates with smear status, time to culture positivity
using liquid culture systems and Xpert CT values.11
The correlation between smear status and bacillary
load as a marker of infectiousness is used to guide
public health and treatment decisions.12 However,
smear status provides a rather crude estimate of
bacillary burden and can only coarsely dichotomise
samples into positive and negative. In settings where
smear microscopy is no longer performed, quantita-
tive Xpert CT may be used to identify infectious TB
patients for contact tracing as recommended by the
WHO.13 Quantitative Xpert CT values may also help
to cost-effectively guide targeted contact tracing of
the most infectious TB patients,14 and thus prioritise
contact tracing.
The present study investigates the association
between Xpert CT values and smear status through
a systematic review of the available literature, and a
meta-analysis using individual-level data provided by
primary studies to establish a receiver operating
characteristic (ROC) curve and optimal cut-offs for
CT values.
METHOD
The review was conducted according to the criteria of
the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses group (PRISMA).15 The protocol
was registered with PROSPERO (CRD42014013315),
and ethical approval was provided by the ethics
committee of the London School of Hygiene &
Tropical Medicine, London, UK (Ref 7071).
Inclusion and exclusion criteria
Cohort, cross-sectional, diagnostic studies, preva-
lence surveys and published and non-published
laboratory validation studies were eligible for inclu-
sion if they reported on respiratory samples (sponta-
neous sputum, induced sputum, broncho-alveolar
lavage, tracheal aspirates, pleural fluid) and provided
culture (either solid or liquid), microscopy (auramine
or Ziehl-Neelsen) and Xpert CT values. Studies were
included if all three diagnostic tests (microscopy,
culture and Xpert) were performed and if the culture
isolate was identified as M. tuberculosis complex
using either nucleic-acid amplification test or antigen
testing. Studies reporting the association between
Xpert CT values and smear status were included in the
descriptive analysis. Authors of studies included in
the descriptive analysis and authors of studies
presenting Xpert, smear microscopy and culture
results were contacted and asked to provide individ-
ual-level data. Studies were excluded if sample sets
were not random or consecutive. We did not exclude
studies that assessed patients during treatment.
Search strategy
A search strategy was developed (see Appendix*) to
identify all relevant studies, regardless of language or
publication status. Medline, Embase, Global Health,
Current Controlled Trials and the Cochrane database
were searched. All references were imported into
EndNote (Thomson Reuters, New York, NY, USA),
duplicates were removed and abstracts were exam-
ined independently by two reviewers. Full-text
articles of all potentially relevant studies were
obtained, and inclusion criteria were applied. Studies
included in three published reviews investigating the
diagnostic accuracy of Xpert were also screened for
inclusion.3,16,17 Reference lists of the studies identi-
fied by the above methods were examined. All
authors of potentially eligible studies were asked at
least twice to provide data sets with individual patient
information (see Appendix for further information on
data extraction).
Risk of bias
Risk of bias for all included studies was assessed
independently (BL and KK). The Cochrane Guide-
lines on Systematic Reviews on Diagnostic Test
Accuracy were followed,18 and the QUADAS-2
(Quality Assessment of Diagnostic Accuracy Studies
*The appendix is available in the online version of this article, at
http://www.ingentaconnect.com/content/iuatld/ijtld/2017/
00000021/00000005/art00005
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2) tool was adapted to assess the risk of bias19
(Appendix).
Data analysis
Meta-analysis was performed using individual-level
data provided by authors. For studies providing
Xpert CT values for each of the probes, a mean CT
value was calculated. For isolates with rpoB muta-
tion, mean CT values were calculated disregarding
the probe with a CT value of 0. Mean Xpert CT
values for smear-positive and smear-negative, cul-
ture-positive samples were calculated. Linear regres-
sion was used to investigate the association between
CT values and smear positivity, smear grading and
days to culture positivity. ROC analysis, stratified by
human immunodeficiency virus (HV) status, was
performed to determine the optimal CT value, taking
into account clustering by patient and study site.
Sensitivity and specificity with corresponding 95%
confidence intervals (CIs) were calculated for
differing cut-off values. All analysis was conducted
using Stata 13 (StataCorp, College Station, TX,
USA).
RESULTS
Study selection
Individual patient data
The last search was performed in February 2016. Of
918 unique citations identified, 92 were deemed
potentially relevant for inclusion in the individual
patient data meta-analysis (Figure 1; Appendix,
information on all studies) and authors were con-
tacted. Fourteen study teams provided anonymised
individual-level data from 15 studies for the meta-
analysis (Table 1).21,25,27,29,30–39
Descriptive systematic review on association
between CT values and smear status
Ten studies investigated the association between
smear status and CT values (Figure 1).11,20,21,26,33–40
Seven of the ten studies were conducted in sub-
Saharan Africa, and HIV prevalence among study
participants ranged from 3% to 60%. Two studies
did not provide information on HIV prevalence.27,36
Overall studies were of moderate to good quality,
although they did not always report on their efforts to
minimise bias. Most, however, were consecutive or
random collections of samples, and nearly all, except
three, did report on the flow of patients in the study
(Table 1).20,34,36
The mean CT values of smear-positive samples
were significantly lower (difference of mean CT
values 3–10) than smear-negative samples.35,36,41
Two studies assessed the association between smear
grade and CT values and found a moderate to good
inverse correlation (Spearman correlation coefficient
range 0.7–0.9).21,36 Three studies performed ROC
analysis and proposed an optimal cut-off CT value for
the detection of smear-positive samples. Cut-offs
Figure 1 Selection process for the inclusion of studies. CT¼cycle threshold.
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derived using Youden’s index (aiming at optimising
sensitivity and specificity) were estimated to be
respectively 27.7, 27.1 and 27.5.21,33,37 The corre-
sponding sensitivity for smear positivity using these
CT value cut-offs ranged from 82% to 98%.21,33,37
One study performed an analysis stratified by HIV
status, and reported an optimal cut-off of 26.7 for
samples from HIV-infected and 28.8 for non-HIV-
infected patients.37
Meta-analysis of individual-level data
Individual-level data from 14 studies and one
unpublished data set were included (Table 1; see
Appendix for description of unpublished data
set).21,25,27,29,30–39 Collectively this amounted to
7511 respiratory samples from 4447 patients. A total
of 1406 patients had at least one culture-positive
sample, 1212 of whom had at least one Xpert-
positive sample, 636 had two Xpert-positive samples
and 11 patients more than three. The total number of
Xpert-positive samples included in the meta-analysis
was 1859. The majority of the samples were from
males (64%); 20% of the samples were smear-
negative, and among those patients with known
HIV (44%) status, 14% were HIV-infected (Table 2).
The mean CT value for smear-positive samples was
significantly lower (22.0, 95%CI 21.5–22.6) than for
smear-negative samples (29.3, 95%CI 28.1–30.5)
(Appendix). Regression analysis revealed a decrease
in CT value of 7.4 (95%CI 8.1 to 6.8) for smear-
positive samples, with 25% of the variability ex-
plained by smear status. Analysis adjusted for sex, age
Table 1 Summary table of the included studies as well as studies providing individual data points (see Appendix for all studies
contacted for individual data points)
Author, year,
reference Country
HIV
%
Specimen
type
Samples
n
Culture-positive
samples
(culture medium:
LG/MGIT)
n
Xpert-positive
n
Smear-positive
(staining method,
concentration)
n
Alnimr, 201420 Saudi Arabia NR Sputum 714 21 (MGIT) 20 17 (Kinyoun staining,
NR)
Blakemore, 201121* Lima, Peru; Baku,
Azerbaijan; Cape
Town and Durban,
South Africa; and
Mumbai, India
40 Sputum 2223 2223 (LG þ MGIT) 2008 1532 (ZN, concentrated
and unconcentrated)
Friedrich, 201322 South Africa,
Tanzania
South Africa 3%,
Tanzania 18%
Sputum 2741 NR (MGIT) NR 221 (auramine, NR)
Friedrich, 201123 South Africa NR Sputum 140 140 (MGIT) 130 120 (auramine, NR)
Hanrahan, 201324 South Africa 60 Sputum 2406 406 (MGIT) 373 210 (auramine,
concentrated)
Nikolayevskyy, 201525* Russia, Lithuania,
Latvia
2–15 Sputum 1937 MGIT NR NR
Rachow, 201126 Tanzania 59 Sputum 292 69 (MGIT þ LJ) 61 51 (ZN, NR)
Theron, 201227* South Africa 30 Sputum 496 141 (MGIT) 130 96 (auramine,
concentrated)
Theron, 201328 South Africa 35 BAL 156 27 (MGIT) 21 16 (auramine,
concentrated)
Theron, 201429* South Africa NR Sputum, BAL 865 172 (MGIT) NR 67
Additional studies providing data for individual-level analysis
Armand, 201130* France NR Sputum, BAL 80 60 (LJ) 44 28 (auramine,
unconcentrated)
Al-Darraji, 201331* Malaysia 100% Sputum 125 15 (MGIT) 8 1 (auramine,
unconcentrated)
Balcells, 201232* Chile 100 Sputum 166 12 (MGIT and LJ) 11 5 (ZN, NR)
Clemente, 201133* Spain NR Sputum, BAL 614 81 (MGIT and LJ) 76 37 (ZN, NR)
Miller, 201134* Canada NR Sputum 89 29 (MGIT þ LJ) 26 2 (auramine)
Ntinginya, 201235* Tanzania NR Sputum 219 9 (MGIT þ LJ) 10 7 (ZN, NR)
Ozkutuk, 201436* Turkey NR Sputum,
tracheal aspirate,
gastric lavage
1611 (1269
patients)
125 (MGIT þ LJ) 101 84 (ZN, concentrated)
Porcel, 201337* Spain NR Pleural fluid 67 5 (LJ) 3 1 (auramine)
Sohn, 201438* Canada 2.4 Sputum 502 25 (MGIT) 12 7 (auramine, NR)
Teo, 201139* Singapore NR Sputum, BAL 131 67 (MGIT) 61 54 (ZN, concentrated)
* Included in the individual-patient data analysis.
HIV ¼ human immunodeficiency virus; LJ ¼ Lo¨wenstein-Jensen; MGITE ¼Mycobacteria Growth Indicator Tube; CT ¼ threshold concentration; ROC ¼ receiver
operator characteristic; NR¼ not reported; AUC¼ area under the ROC curve; ZN¼ Ziehl-Neelsen; BAL¼ bronchoalveolar lavage.
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and HIV status including 812 samples revealed
similar results (7.5, 95%CI 8.4 to 6.5). Sputum
samples of HIV-infected individuals had higher CT
values than non-HIV-infected individuals (regression
coefficient 2.7, 95%CI 1.2–4). A sensitivity analysis
disregarding the biggest sample set21 yielded a
coefficient of6.9 for smear-positive samples; anoth-
er sensitivity analysis disregarding frozen or archived
samples yielded a coefficient of7.1 (Table 3).
Smear grading and CT values
Smear grading was available for 1428 samples. A
subanalysis adjusted for sex, age and HIV status
including 621 records showed a linear association
between smear grade and CT values. Using scanty
smears as the reference, the regression coefficients were
respectively 3.2 (95%CI 4.1 to 2), 5.3 (95%CI
66 to4) and9.4 (95%CI10.6 to8.3) for 1þ, 2þ
and 3þ smear-positive samples (Table 3, Figure 2A).
Including smear grade as a linear variable yielded a
regression coefficient of3.1 (95%CI3.4 to2.8).
CT value and days to culture positivity
Data on days to culture positivity were provided for
1424 samples. A linear regression of CT value and
days to culture positivity showed evidence of a
positive association (P , 0.001). The average
increase in CT value was 0.18 for each extra day to
culture positivity (95%CI 0.12–0.24) in a linear
regression accounting for clustering by participants
and adjusting for HIV, sex, age and study location (n
¼ 776 ) (Figure 2B and Table 3).
Receiver operator characteristic analysis
ROC analysis, adjusted for study location and
accounting for clustering by patient, was performed
Table 1 (continued)
Correlation between
CT value and
bacterial load
CT value cut-off
(ROC analysis)
Sensitivity for
proposed
CT cut-off
Specificity for
proposed
CT cut-off
Risk of
bias Storage
Spearman’s correlation coefficient r
¼ 0.9 (CT value and time to
culture positivity)
NR NR NR Moderate Fresh samples
r ¼ 0.77 (CT value and smear
microscopy grading)
27.7 suggested as most
predictive cut off; 25 for
higher specificity; AUC NR
(only samples with internal
control CT value of ,34)
CT value 27.7: 98%
CT value 25: 95%
CT value 27.7: 48%
CT value 25: 65%
Low Fresh samples,
r ¼ 0.74 (CT value and smear
microscopy grading)
r ¼ 0.73 (CT value and days to
culture positivity)
Different cut-offs throughout
treatment
NR NR Moderate Fresh samples
r ¼ 0.40 (CT value and smear
microscopy grading)
r ¼ 0.54 (CT value and days to
culture positivity)
NR NR NR Moderate Fresh samples
r ¼ 0.58 (CT value and days to
culture positivity)
Overall: 27.5, HIVþ:26.7, HIV:
28.8 AUC NR
Overall: 69%,
HIVþ: 79%,
HIV: 56
NR Low One fresh,
one frozen
r ¼ 0.61 (CT value and days to
culture positivity)
NR NR NR Moderate Fresh samples
b ¼ 5.02 (CT value and smear
microscopy grading) b ¼ 1.19 (CT
value /days to culture positivity)
NR NR NR Moderate Frozen samples
Smearþ: CT value 22
Smear:CT value 32.6
CT value 27.1 cut off suggested
as most predictive
CT value , 31.8 suggested as
a rule out AUC 0.86
CT 27.1: 82%,
CT 31.8: 96%
CT 27.1:79%
CT 31.8:47%
Low Frozen samples
r ¼ 0.50 (CT value and time to
culture positivity)
NR NR NR Low Frozen samples
r ¼ 0.50 (CT value and days to
culture positivity)
NR NR NR NR Fresh samples
NR NR NR NR Moderate Fresh samples
NR NR NR NR Low Fresh samples
NR NR NR NR Low Fresh samples
NR NR NR NR Moderate Fresh samples
NR NR NR NR Moderate Frozen samples
NR NR NR NR Moderate Fresh samples
NR NR NR NR Moderate Fresh samples
NR NR NR NR Moderate Frozen samples
NR NR NR NR Low Fresh samples
NR NR NR NR High Fresh samples
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to determine the area under the curve (AUC) and
sensitivity and specificity for specific CT value cut-
offs (Figure 3). The overall AUC was 0.85 (95%CI
0.82–0.87), and remained the same when stratified by
HIV status. Sensitivity and specificity for different CT
value cut-offs stratified by HIV status are shown in
Table 3. Overall, a CT value cut-off at 27.7 would
provide a sensitivity of 85% (95%CI 83–87) and a
specificity of 67% (95%CI 66–77). In non-HIV-
infected individuals, the same cut-off would have a
Table 2 Baseline characteristics for individual-level data of patients with culture-positive and Xpert-positive samples*
Smear-negative
n (%)
Smear-positive
n (%)
Unknown
n (%)
Total
n (%)
Age, years, median† 37 32 44 33
Sex
Male 159 (64) 554 (59) 15(62) 728 (60)
Female 70 (28) 243 (26) 9 (37) 322 (27)
Missing 18 (7) 144 (15) 0 162 (14)
HIV status
Negative 62 (25) 318 (34) 12 (50) 392 (32)
Positive 50 (20) 91 (10) 11 (46) 152 (13)
Missing 153 (55) 532 (57) 1 (4) 668 (55)
Treatment status
Unknown 107 (43) 461 (38) 23 (96) 591 (49)
Treatment not yet started 102 (41) 339 (36) 1 (4) 442 (36)
Completed treatment 37 (15) 105 (11) 0 142 (12)
Stopped treatment 1 (1) 36 (4) 0 37 (3)
Specimen
Sputum 224 (91) 898 (95) 24 (100) 1146 (95)
BAL 20 (8) 39(4) 0 59 (5)
Tracheal aspirate 0 2 (1) 0 2 (0.2)
Pleural fluid 3 (1) 2 (1) 0 5 (0.2)
Author, reference, country
Al-Darraji,30 Malaysia 5 (2) 1 (0.1) 0 6 (0.5)
Armand,28 France 17 (8) 27 (4) 0 44 (5)
Balcells,25 Chile 5 (3) 6 (1) 0 11 (1)
Blakemore,21 Peru, Azerbaijan, South Africa, India 126 (51) 504 (54) 0 630 (52)
Clemente,22 Spain 19 (9) 31 (4) 1 (4) 51 (5)
Kalmambetova, Kyrgyzstan (unpublished) 11 (5) 103 (11) 0 114 (9)
Miller,33 Canada‡ 2 (1) 9 (1) 0 11 (1)
Ntinginya,23 Tanzania 1 (0.5) 5 (0.7) 0 6 (1)
Nikolayevskyy,20 Russia, Lithuania, Latvia 4 (2) 27 (3) 0 31 (3)
Ozkutuk,31 Turkey 17 (7) 67 (7) 0 84 (7)
Porcel,32 Spain‡ 1 (0.4) 1 (0.1) 2 (0.2)
Sohn,29 Canada 4 (2) 6 (1) 0 10 (1)
Theron,42 South Africa‡ 8 (4) 23 (3) 23 (95) 54 (5)
Teo,24 Singapore 5 (2) 42 (6) 0 47 (5)
Theron,42 South Africa 22 (9) 89 (10) 0 111 (9)
Total, n 247 941 24 1212 (100)
*No missing values for smear status.
†Missing values: smear-negative (n¼ 18), smear-positive (n¼ 103).
‡ Data include frozen samples processed for Xpert, see Table 3 for sensitivity analysis.
HIV¼ human immunodeficiency virus; BAL¼ bronchoalveolar lavage.
Table 3 Random effects linear regressions on CT value, smear status, smear grading and days to culture positivity
Explanatory variable as measure for bacillary load b coefficient P value 95%CI
Smear status (1827 samples from 1167 patients) (crude*)† Smear-positive 7.4 ,0.001 8.1 to 6.8
Smear status (812 samples from 515 patients)*‡§ Smear-positive 7.5 ,0.001 8.4 to 6.5
Time to culture positivity in days (776 samples from 528 patients)*‡ 1 day 0.18 ,0.001 0.12 to 0.24
Smear grade (621 samples from 393 patients)*‡
Scanty Baseline
1þ 3.2 ,0.001 4.4 to 2
2þ 5.3 ,0.001 6.6 to 4
3þ 9.4 ,0.001 10.6 to 8.3
*Clustering by patient and study site accounted for.
† In a sensitivity analysis, a variable for storage conditions (frozen vs. fresh samples) was included in the linear regression of 1827 samples from 1167 patients. The
regression coefficient for smear-positive samples did not change and there was no evidence for an association of CT values as to whether samples were frozen or
not (P¼ 0.81).
‡ Adjusted for sex, age and HIV status.
§ In a sensitivity analysis removing the biggest study (.50% of samples, Blakemore),21 performing the same regression analysis on 208 samples from all other
studies, the b coefficient for smear-positive samples compared to smear-negative samples was6.9 (95%CI8.3 to5.5).
CT¼ threshold concentration; CI¼ confidence interval; HIV¼ human immunodeficiency virus.
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sensitivity of 83% (95%CI 79–86) and a specificity of
62% (95%CI 51–71), while in HIV-infected patients
sensitivity would be 79% (95%CI 70–85) and
specificity 79% (95%CI 65–88). To raise sensitivity
to 95% (95%CI 94–96), the overall cut-off would
have to be set at 31.8, resulting in a specificity of 35%
(95%CI 30–41) (Table 4 and Figure 3).
DISCUSSION
Key findings
This review confirms the consistent, strong associa-
tion between Xpert CT values and the bacillary load,
through both a descriptive review of the literature and
a meta-analysis of 1859 samples. Three of 10 studies
included in the descriptive review conducted ROC
analysis and reported CT value cut-offs of between
27.1 and 27.7 for optimal specificity (48–79%) and
sensitivity (82–98%). Data on 1859 Xpert-positive
respiratory samples from 1212 patients were included
in the meta-analysis. The mean difference in CT
values between smear-positive and smear-negative
samples was 7.4. The ROC curve showed good
diagnostic accuracy (AUC 0.85).
Strengths and limitations
The strengths of this review include a broad search
strategy across different databases without any
restrictions with regard to language and setting.
Despite our best efforts, only 14/92 potentially
eligible studies and one previously unpublished data
set could be included in the meta-analysis. While
some studies could not be included due to the lack of
CT values, authors of other studies presenting data on
CT values and smear status were unable to provide
individual-level data.34–36 The data included in the
meta-analysis thus presents a selection, and might be
prone to bias. One study provided .50% of all
samples, which might have disproportionately influ-
enced our results. However, sensitivity analysis
excluding this study revealed similar results. The
overall quality of the included studies was moderate
to good, and risk of bias within studies was low.
Interpretation of findings
The general association between Xpert CT values and
bacillary load is not new, and mirrors what individual
studies have shown.11,21 Our meta-analysis allows
for detailed and context-dependent analysis of this
relationship for programmatic purposes. The moder-
ate diagnostic accuracy of CT values compared to
smear in this meta-analysis, as well as different needs
in contexts with varying prevalence of smear positiv-
ity, might preclude the use of CT values as a
replacement for smear in every context.
Deciding which CT cut-off to use will differ
according to the required objectives and context. To
detect 95% of smear-positive patients, a cut-off of
31.8 would have to be chosen, resulting in a low
(35%) specificity and lower positive predictive value.
In the context of scarce resources, patients with the
lowest CT value, such as 20.7, might be prioritised for
isolation. A recent cost-effectiveness study from the
United States suggested that the use of Xpert in
guiding decisions on patient isolation could substan-
tially reduce isolation time as well as costs.42
In the context of contact tracing, CT cut-offs may
Figure 2 Association between A) CT values (medians, 25 and
75 percentiles and ranges) and smear grading; B) CT values and
days to culture positivity (grey line¼ regression; grey area¼area
of 95% confidence intervals. CT¼ threshold concentration. This
image can be viewed online in colour at http://www.
ingentaconnect.com/content/iuatld/ijtld/2017/00000021/
00000005/art00005
Figure 3 ROC of CT value on smear, adjusting for study
location and taking into account patient clustering by HIV
status. HIV ¼ human immunodeficiency virus; CT ¼ threshold
concentration; ROC¼ receiver operating characteristic.
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be chosen according to resource availability. A CT
value cut-off of 27.7 would result in 59% of
individuals being labelled as ‘highly infectious’ in a
setting where 50% of patients with pulmonary TB are
smear-positive. The CT value cut-off would thus
identify a similar number of highly infectious index
cases as smear microscopy, and result in a similar
number of contact tracing activities. However, 28%
of these index cases identified by CT value cut-off
would be smear-negative, and 15% of the index cases
identified as less infectious would be smear-positive.
The sensitivity of CT value cut-offs will always be less
than 100%. However, smear positivity alone is itself
an imperfect measure of infectiousness,12,43 and
transmission from smear-negative, culture-positive
index cases is well described.44 CT values are
generated in a consistent automated fashion, are less
operator-dependent than smear microscopy, produce
a timely available read-out, do not require any
interpretation and are thus more objective. Whether
smear status or Xpert CT values predict infectiousness
more accurately remains to be shown in prospective
controlled studies.
With regard to treatment monitoring, CT values
provide a theoretical advantage of being able to
compare numerical values over time rather than
comparing two broad categories. In this paper, we did
not specifically assess CT values for their value in
treatment monitoring. However, a multicentre trial
conducted in sub-Saharan Africa failed to show any
association between Xpert results and treatment
outcomes in patients with drug-susceptible TB,
despite good correlation between Xpert CT values
and smear status.38 It is therefore difficult at this
point to judge the usefulness of CT values for serial
testing of patients as part of treatment monitoring.2
A limitation inherent to smear microscopy and Xpert
is the inability to differentiate between viable and dead
bacilli. This differentiation is particularly important in
patients on treatment. This has been addressed in the
context of the Xpert test that uses propidium mono-
azide.20 CT values of samples treated with propidium
monoazide were consistently lower than CT values of
untreated samples. Further research is needed to assess
whether Xpert, with or without propidium monoazide
pretreatment, could substitute smear microscopy for
the purpose of treatment monitoring.
In conclusion, this meta-analysis provides further
evidence that Xpert CT values are strongly associated
with smear status. However, the important question
of whether Xpert CT values predict infectiousness,
transmission and treatment response remains unan-
swered. The correlation between Xpert CT values and
bacillary load is biologically plausible and supported
by the results of this review. Given that mycobacillary
burden on an individual level is linked to onward M.
tuberculosis transmission, it may even be that
aggregated Xpert CT values at a community level
(akin to community mycobacterial load) could
potentially be used as a marker of ongoing commu-
nity transmission, a concept similar to community
viral load in the context of HIV.45
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ratio;þ¼ positive;¼ negative; HIV¼ human immunodeficiency virus.
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APPENDIX
Search strategy for systematic review
We searched the following databases: 1) Medline, 2)
Embase, 3) Global Health, 4) Current Controlled
Trials, and 5) Cochrane Database of Systematic
Reviews. The search strategy for Medline is given
below. Search strategies were adapted to the data-
bank used, but essentially we tried to retrieve all
references that covered tuberculosis as well as the use
of Xpertw MTB/RIF. We only searched for references
from 2006 onward, as Xpert was not in use before
that. We did not restrict by language or country.
Data extraction and management
Data were extracted independently in duplicate
using a standardised data extraction form. Data
regarding setting, laboratory procedures (culture
and microscopy methods), study population eligi-
bility (inclusion and exclusion) criteria, population
size, human immunodeficiency virus status, number
of samples and diagnostic results (Xpert threshold
concentration [CT] value, smear result, smear
grading, culture result, time to culture positivity)
were determined. For studies included in the
descriptive analysis, the following additional infor-
mation was obtained where applicable: CT value
cut-offs for smear-positive samples determined by
receiver operating characteristic (ROC) analysis,
Spearman’s correlation coefficient, regression coef-
ficient and mean CT values for smear-positive and
smear-negative samples. Authors were asked to
provide the following essential information for the
data sets included in the meta-analysis: patient
identifier, name and location of the laboratory, type
of specimen, date of culture, date of microscopy,
microscopy method, culture method, Xpert process-
ing date, culture result, microscopy result, Xpert
result, Xpert CT value. Where authors provided all
sample CT values on individual probes A–E, a mean
was calculated; CT values of individual probes
rifampicin-resistant (and therefore 0) were excluded.
Authors were asked to provide any of the additional
information if available: sex and age of the patient,
human immunodeficiency virus (HIV) status, treat-
ment status, smear grading, time to culture positivity
on liquid culture.
Information on the unpublished data set
The data set contains data on 170 successive samples
of 170 patients from the National Reference Labo-
ratory in Kyrgyzstan from 2013 and 2014. Only
samples with information available on culture,
microscopy and Xpert results were provided, in an
anonymised manner. No information on HIV status
or time to culture positivity was available. The data
set was provided by G Kalmambetova, Head of the
Laboratory.
Table A.1 Search strategy for systematic review
Databank Category Search terms
Medline XpertW MTB/RIF Xpert.mp
Genexpert.mp
Cepheid.mp
gene adj1 xpert.mp
qRT adj1 PCR.mp
Tuberculosis exp Tuberculosis
exp Mycobacterium tuberculosis
Tuberculosis.mp
TB.mp
Tb.mp
Mycobacteriosis.mp
Mycobacterium.mp
Mtb.mp
Xpert CT values to predict smear status in TB i
Table A.2 All studies potentially able to provide individual level patient data:83–92 studies included in the descriptive systematic
review on CT values, in grey studies contributing individual-level data to the meta-analysis
Study data
Author,
reference Study title Journal Country Year
Samples/patients
n
Study
population
Al-Darraji1 The diagnostic performance of a single Xpert MTB/
RIF assay in an intensified tuberculosis case
finding survey among HIV-infected prisoners in
Malaysia
PLOS ONE
(electronic
resource)
Saudi Arabia 2013 125 patients 125 HIV infected
prisoners
Al-Ateah2 Evaluation of direct detection of Mycobacterium
tuberculosis complex in respiratory and non-
respiratory clinical specimens using the Cepheid
Gene Xpert system
Saudi Med J Saudi Arabia 2012 239 total, 172 respiratory
samples, 62 samples
positive by culture
Patients tested for TB
Al Johani3 Rapid molecular detection of tuberculosis and
rifampin resistance using Xpert MTB/RIF
Conference
abstract
Saudi Arabia 2011 26 culture-positive, 16 smear-
positive, 40 persons without
TB
Patients tested for TB
Antonenka4 Comparison of Xpert MTB/RIF with ProbeTec ET DTB
and COBAS TaqMan MTB for direct detection of
M. tuberculosis complex in respiratory specimens
BMC Infect Dis Germany 2013 121 sputum samples, 68
culture-positive
Patients tested for TB
Archontakis5 Evaluation of GeneXPERT MTB/RIF assay in
respiratory and non-respiratory specimens for the
rapid detection of Mycobacterium tuberculosis
Conference
abstract
Greece 2011 250 samples, 50 culture-
positive, 24 M. tuberculosis
complex, 14 respiratory
samples
Patients tested for TB
Armand6 Comparison of the Xpert MTB/RIF test with an
IS6110-TaqMan real-time PCR assay for direct
detection of Mycobacterium tuberculosis in
respiratory and non-respiratory specimens
J Clin Microbiol France 2011 117 clinical specimens (97
culture-positive and 20
culture-negative, 60
respiratory and 37 non-
respiratory specimens
Unclear
Atehortua7 Xpert MTB/RIF test performance assay in respiratory
samples at real work settings in a developing
country
Biomedica Colombia 2015 152 eligible, 103 patients
included
Patients tested for TB
Aurin8 Molecular approaches for detection of the multi-
drug resistant tuberculosis (MDR-TB) in
Bangladesh
PLOS ONE Bangladesh 2014 300 samples, 193 RMP
resistance detected
Patients tested for TB with
suspicion of resistance
Balcells9 Rapid molecular detection of pulmonary
tuberculosis in HIV-infected patients in Santiago,
Chile
Int J Tuberc Lung
Dis
Chile 2012 12 culture-positive samples 166 HIV-positive patients
Barnard10 The diagnostic performance of the GenoType
MTBDRplus version 2 line probe assay is
equivalent to that of the Xpert MTB/RIF assay
J Clin Microbiol South Africa 2012 282 samples NR
Barnard11 The utility of Xpert MTB/RIF performed on bronchial
washings obtained in patients with suspected
pulmonary tuberculosis in a high prevalence
setting
BMC Pulm Med South Africa 2015 112 patients for bronchial
lavage, 39 culture-positive
Patients tested for TB with
negative or scarce
smear
Barreales12 GeneXpert MTB/RIF system in pulmonary and extra-
pulmonary specimens: comparison with other
nucleic acid technologies
Conference
abstract
Spain 2012 90 samples, 50 respiratory, 11
smear-positive, 79 smear-
negative
NR
Bilgin13 Comparison of a real-time polymerase chain
reaction-based system and Erlich-Ziehl-Neelsen
method with culture in the identification of
Mycobacterium tuberculosis
Turk J Med Sci Turkey 2016 243 respiratory samples Patients tested for
tuberculosis
Bodmer14 Diagnosing pulmonary tuberculosis in a low
prevalence setting—the Xpert MTB/RIF tes
Conference
abstract
2010 231 specimens, 6 culture-
positive
149 patients tested for TB
Boehme15 Rapid molecular detection of tuberculosis and
rifampin resistance
N Engl J Med Multisite 2010 732 culture-positive patients,
561 smear-positive, 171
smear-negative
NR
Boehme16 Feasibility, diagnostic accuracy, and effectiveness of
decentralised use of the Xpert MTB/RIF test for
diagnosis of tuberculosis and multidrug
resistance: a multicentre implementation stud
Lancet Multisite 2011 6648 participants
evaluated for TB
Bowles17 Xpert MTB/RIF, a novel automated polymerase chain
reaction-based tool for the diagnosis of
tuberculosis
Int J Tuberc Lung
Dis
The Netherlands 2011 72 samples Patients tested for TB
Bunsow18 Evaluation of GeneXpert MTB/RIF for the detection
of Mycobacterium tuberculosis and resistance to
rifampin in clinical specimens
J Infect Spain 2014 595 clinical samples, 290
respiratory, 81 culture-
positive
Patients tested for TB
Carriquiry19 A diagnostic accuracy study of Xpert MTB/RIF in HIV-
positive patients with high clinical suspicion of
pulmonary tuberculosis in Lima, Peru
PLOS one Peru 2012 131 HIV positive Patients
tested for TB
Celik20 Applicability of Xpert MTB/RIF assay for routine
diagnosis of tuberculosis: a four-year single-center
experience
Turk J Med Sci Turkey 2015 7407 samples from patients
without suspicion of TB, 411
samples from patients with
high risk of TB
Patients screened for TB
Ciftci21 [Evaluation of Xpert MTB/RIF results for the
detection of Mycobacterium tuberculosis in
clinical samples]
Mikrobiyol Bul Turkey 2011 85 samples, 25 culture-
positive
Clemente22 Evaluation of the Xpert MTB/RIF test for rapid
detection of Mycobacterium tuberculosis
Conference
abstract
Spain 2011 1039 samples, 614 pulmonary,
81 culture-positive
930 patients tested for TB
Darwish23 Diagnostic assessment of Xpert MTB/RIF in a sample
of Mycobacterium tuberculosis Egyptian patients
Afr J Microbiol Res Egypt 2013 50 samples Patients tested for TB
Davis24 The clinical and public health impact of automated
nucleic acid testing for TB evaluation in San
Francisco
Conference
abstract
US 2011 20 samples 20 patients tested for TB
on empiric treatment
Davis25 Impact of GeneXpert MTB/RIF on patients and
tuberculosis programs in a low-burden setting. a
hypothetical trial
Am J Respir Crit
Care Med
US 2014 156 patients, 59 empiric TB
treatment
Patients tested for TB
Deforges26 Application of the rapid detection system for M.
tuberculosis complex and rifampicin resistance
Xpert MTB/RIF in decontaminated respiratory
specimens, non-respiratory specimens and
cultures
Conference
abstract
France 2010 15 pulmonary samples, 10
culture-negative, 2 NTM-
positive, 3 culture-positive
Patients tested for TB
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Table A.2 (continued)
Study data Xpert sensitivity and specificity
Comments
Inclusion criteria for this systematic review
HIV
%
Sensitivity
(vs. culture)
%
Smearþ
% Smear
Specificity
(vs. culture)
Culture
analysed
Smear
analysed
Xpert
analysed
CT values
reported or
analysed
Median time
to culture
positivity
NR 53.3 100 NR NR Yes Yes Yes No No
NR 95.4 NR NR 100 Respiratory and non-
respiratory
Yes Yes Yes No No
NR 96.2 93.80 25 NR Unclear number of people Yes Yes Yes No No
NR 74.6 100 68 96.2 Frozen specimens Yes Yes Yes No No
NR 100 NR NR NR Very few respiratory samples Yes Unclear Yes No No
NR 78.7 100 57 1 Yes Yes Yes No Yes
NR 91 NR 87 92 Spanish paper Yes Yes Yes NR NR
NR NR NR NR NR Mainly on RMP-resistant
samples but not limited to
these
Yes Yes Yes No No
100 11/12 (91.7)
(95%CI 64.6–
98.5)
8/12 (66.7)
(95%CI 39.1–
86.2)
NR 147/148 (99.3)
(95%CI 96.3–
99.9)
Yes Yes Yes No Yes
NR 71.2 NR 58 100 Yes Yes Yes No Yes
NR 92.3 NR NR 87.7 Yes Yes Yes NR NR
NR 100 100 100 100 Yes Yes Yes No No
NR 100 NR NR 98.7 Yes Yes Yes NR NR
83.3 (95%CI
43.6–96.9)
100 (95%CI 98.3–
100)
Yes Yes Yes No No
40.2 92 98.2 72.5 99.2 Yes Yes Yes No No
19 90.3 77 99 Yes Yes Yes No Yes
93.8 NR NR 92 Yes Yes Yes No No
NR 97.1 NR NR 95 Yes Yes Yes No No
100 97.8 (95%CI
88.4–99.6)
NR NR 84/86 (97.7)
(95%CI 91.9–
99.4)
Yes Yes Yes No No
NR 100 NR NR 99 Yes Yes Yes NR NR
96 NR NR NR Article in Turkish Yes Yes Yes No No
93 1 92.3 100 Yes Yes Yes No No
NR 97.1 NR NR 100 Yes Yes Yes No No
NR NR NR NR NR Yes Yes Yes No No
NR NR NR NR NR Yes Yes Yes No No
NR 100 NR NR NR Yes Yes Yes No No
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Table A.2 (continued)
Study data
Author,
reference Study title Journal Country Year
Samples/patients
n
Study
population
Deggim27 Integrating the Xpert MTB/RIF assay into a
diagnostic workflow for rapid detection of
Mycobacterium tuberculosis in a low-prevalence
area
J Clin Microbiol Switzerland 2013 79 samples, 57 sputum
samples, 10 bronchial
aspirates, 4 BAL, 8 non-
respiratory samples
Patients tested for TB
Dorman28 Performance characteristics of the Cepheid Xpert
MTB/RIF test in a tuberculosis prevalence survey
PLOS ONE South Africa 2012 6893 samples, 187 culture-
positive
6893 participants of
prevalence survey
Gascoyne29 Comparison of on-demand PCR testing for
Mycobacterium tuberculosis with culture and
batched PCR
Conference
abstract
UK 2012 96 samples Patients tested for TB
Geleta30 Xpert MTB/RIF assay for diagnosis of pulmonary
tuberculosis in sputum specimens in remote
health care facility
BMC Microbiol Ethiopia 2015 227 paired sputum samples Patients tested for TB
Handel31 The impact of XpertW MTB/RIF in sparsely populated
rural settings
Int J Tuberc Lung
Dis
South Africa 2015 1449 persons tested for TB Patients tested for TB
Hanif32 GeneXpert MTB/RIF for rapid detection of
Mycobacterium tuberculosis in pulmonary and
extra-pulmonary samples
Int J Tuberc Lung
Dis
Kuwait 2011 206 pulmonary (196 sputum,
6 BAL, 4 endotracheal
aspirate), 60 pulmonary
samples culture-positive
Hanrahan33 Time to treatment and patient outcomes among
patients tested for TB screened by a single point-
of-care Xpert MTB/RIF at a primary care clinic in
Johannesburg, South Africa
PLOS ONE
(electronic
resource)
South Africa 2013 641 patients with suspected
TB, 50 Xpert-positive
samples
Helb34 Rapid detection of Mycobacterium tuberculosis and
rifampin resistance by use of on-demand, near-
patient technology
J Clin Microbiol Viet Nam 2010 107 clinical sputum samples
Ionnaidis35 Cepheid GeneXpert MTB/RIF assay for
Mycobacterium tuberculosis detection and
rifampin resistance identification in patients with
substantial clinical indications of tuberculosis and
smear-negative microscopy results
J Clin Microbiol Greece 2011 121 samples, 80 pulmonary
and 41 extra-pulmonary,
from 108 patients
Patients tested for TB
Jafari36 Comparison of molecular and immunological
methods for the rapid diagnosis of smear-
negative tuberculosis
Int J Tuberc Lung
Dis
Germany 2013 96 patients tested for TB, BAL
samples
Patients tested for TB
Kim37 The Xpert MTB/RIF assay evaluation in South Korea,
a country with an intermediate tuberculosis
burden
Int J Tuberc Lung
Dis
South Korea 2012 71 specimens TB patients
Kim38 Identification of Mycobacterium tuberculosis and
rifampin resistance in clinical specimens using the
Xpert MTB/RIF assay
Ann Clin Lab Sci South Korea 2015 444 samples of 383 patients
with suspected TB who
were hospitalised
Patients with suspected
TB
Kim39 Comparison of the Xpert MTB/RIF assay and real-
time PCR for the detection of Mycobacterium
tuberculosis
Ann Clin Lab Sci South Korea 2015 52 samples Patients with suspected
tuberculosis
Kurbatova40 Performance of CepheidW Xpert MTB/RIFW and TB-
BiochipW MDR in two regions of Russia with a
high prevalence of drug-resistant tuberculosis
Eur J Clin
Microbiol Infect
Dis
2013 238 specimens, 109 culture-
positive, 67 RMP-resistant
Patients tested for TB
Kwak41 Diagnostic accuracy and turn-around time of the
Xpert MTB/RIF assay in routine clinical practice
PLOS ONE
(electronic
resource)
South Korea 2013 681 patients Patients tested for TB
Lawn42 Screening for HIV-associated tuberculosis and
rifampicin resistance before antiretroviral therapy
using the Xpert MTB/RIF assay: a prospective
study
PLOS ONE South Africa 2011 839 samples, 81 culture-
positive
515 HIV-positive patients
tested for TB, 17.3%
TB prevalence
Lee43 Diagnostic accuracy of XpertW MTB/RIF on
bronchoscopy specimens in patients with
suspected pulmonary tuberculosis
Int J Tuberc Lung
Dis
South Korea 2013 132 patients with Xpert, 38
culture-positive
Patients tested for TB
Lin44 Evaluation of Xpert MTB/RIF assay and amplified
Mycobacterium tuberculosis Direct test in direct
detection of pulmonary M. tuberculosis complex
Conference
abstract
China 2010 38 smear positive samples, 27
culture-positive
Patients tested for TB
Lin45 Comparative evaluation of GeneXpert MTB/RIF
assay and Gen-Probe amplified Mycobacterium
tuberculosis Direct test for detection of
Mycobacterium tuberculosis complex in smear-
negative respiratory specimens
Conference
abstract
China 2011 21 smear-negative culture-
positive
Patients tested for TB
Lorent46 Active tuberculosis screening of close contacts
among the urban poor: a Cambodian experience
Int J Tuberc Lung
Dis
Cambodia 2014 1171 sputum samples from
close contacts to TB
Close contacts
Luetkemeyer47 Xpert MTB/RIF versus AFB smear to determine
respiratory isolation of US TB suspects
Conference
abstract
US 2015 633 samples Patients with suspected
TB
Malbruny48 Rapid and efficient detection of Mycobacterium
tuberculosis in respiratory and non-respiratory
samples
Int J Tuberc Lung
Dis
France 2011 91 respiratory, 17 culture-
positive
132 patients tested for TB
Marlowe49 Comparison of three molecular methods for the
direct detection of Mycobacterium tuberculosis
complex from respiratory & non-respiratory
specimens
Conference
abstract
US 2010 76 specimen, 40 sputum, 11
bronchial
Patients tested for TB
Marlowe50 Evaluation of the Cepheid Xpert MTB/RIF assay for
direct detection of Mycobacterium tuberculosis
complex in respiratory specimens
J Clin Microbiol US 2011 217 specimens Patients tested for TB
Matabane51 Performance evaluation of three commercial
molecular assays for the detection of
Mycobacterium tuberculosis from clinical
specimens in a high TB-HIV-burden setting
BMC Infect Dis South Africa 2015 90 samples, 81 analysable Persons tested for TB
Miller52 Performance of Xpert MTB/RIF RUO assay and
IS6110 real-time PCR for Mycobacterium
tuberculosis detection in clinical samples
J Clin Microbiol US 2011 112 specimen, 89 pulmonary,
29 culture-positive
pulmonary
90 patients tested for TB
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Table A.2 (continued)
Study data Xpert sensitivity and specificity
Comments
Inclusion criteria for this systematic review
HIV
%
Sensitivity
(vs. culture)
%
Smearþ
% Smear
Specificity
(vs. culture)
Culture
analysed
Smear
analysed
Xpert
analysed
CT values
reported or
analysed
Median time
to culture
positivity
NR NR 100 NR NR Yes Yes Yes No No
8.7 self-reported
positive
62.6 (95%CI
55.2–69.5)
97.0 (95%CI
84.2–99.9)
55.2 (95%CI
47.0–63.2)
99.6 (95%CI
99.4–99.7),
81.3 (95%CI
73.9–87.3)
Yes Yes Yes No No
NR 96 NR NR 98 Yes Yes Yes No No
NR 65.5 NR 31 NR Yes Yes Yes NR NR
91–99 (depending
on
centralisation)
NR NR NR Yes Yes Yes NR NR
NR 92 98 69 Yes Yes Yes No No
69 66 NR NR NR Yes Yes Yes No Yes
NR 91 100 84.6 Yes Yes Yes No No
NR 90.6 NR NR 93.5 NR Yes Yes Yes No No
NR 60 NR NR 97 Compared to T. SPOT Yes Yes Yes No No
0 100 NR NR NR NR Yes Yes Yes No Yes
74 NR NR NR Yes Yes Yes NR NR
NR 75.5 93.8 65.5 NR Yes Yes Yes NR NR
NR 95.3 (95%CI
90.0–98.3)
NR NR 86.0 (95%CI
78.9–91.3)
NR Yes Yes Yes No No
0.7 79.50 NR NR 100 Median time to treatment
markedly reduced in
those with Xpert
Yes Yes Yes No 7 days
NR 73.3 100 43.4 (one sample);
62.3 (two
sample)
NR Yes Yes Yes No Yes
0.8 81.60 NR NR 100 Yes Yes Yes No No
NR 92.6 NR NR NR Yes Yes Yes No No
NR NR NR 52.4 NR Yes Yes Yes No No
NR NR NR NR NR Yes Yes Yes No No
38 82 NR NR NR Yes Yes Yes NR NR
NR 100 NR NR 100 Yes Yes Yes No No
NR 97.7 NR NR 100 Archived samples Yes Yes Yes No No
NR 0.96 0.98 0.72 Yes Yes Yes No No
89.1 NR NR NR Yes Yes Yes NR NR
NR 93 100 60 97 Yes Yes Yes No No
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Table A.2 (continued)
Study data
Author,
reference Study title Journal Country Year
Samples/patients
n
Study
population
Mokkaddas53 Comparison of two nucleic acid amplification
assays, the ProbeTec ET assay and Xpert MTB/RIF
assay, for detection of Mycobacterium
tuberculosis in pulmonary and extra-pulmonary
specimens
Conference
Abstract
Kuwait 2012 989 specimen, 90 smear-
positive, 66 smear-negative,
833 culture-negative
NR
Mokkaddas54 Evaluation of Gene Xpert MTB/RIF system for the
direct detection of rifampicin-resistant
Mycobacterium tuberculosis from pulmonary and
extra-pulmonary specimens in the National
Tuberculosis Reference Laboratory in Kuwait
Conference
Abstract
Kuwait 2011 236 specimens, pulmonary
196
NR
Myneedu55 XpertW MTB/RIF assay for tuberculosis diagnosis:
evaluation in an Indian setting
Int J Tuberc Lung
Dis
India 2014 134 samples from patients 134 TB patients with
suspicion of resistance
Naidoo56 Evaluation of GeneXpert MTB/RIF assay on
pulmonary and extra-pulmonary samples in a
high-throughput laboratory
Conference
Abstract
South Africa 2010 1140 sputum samples Patients tested for TB
Narute57 Comparative study of gene Xpert MTB/RIF, smear
microscopy and TB MGIT culture in diagnosis of
tuberculosis in India
Conference
abstract
India 2015 63 pulmonary TB patients
Nazli58 Evaluation of GeneXpert MTB/RIF assay for the
diagnosis of tuberculosis and rapid detection of
rifampin resistance in clinical specimens
Conference
Abstract
Turkey 2011 232 specimen, 28 smear
positive, 69 culture positive
228 patients
Nosova59 [Comparing performance of ‘TB-BIOCHIP’, ‘Xpert
MTB/RIF’ and ‘GenoType MTBDRplus’ assays for
fast identification of mutations in the
Mycobacterium tuberculosis complex in sputum
from TB patients]
Mol Biol (Mosk) Russia 2013 NR Patients tested for TB
Ntinginya60 Performance of the XpertW MTB/RIF assay in an
active case-finding strategy: a pilot study from
Tanzania
Int J Tuberc Lung
Dis
Tanzania 2012 219 enrolled contacts, 5
culture positive
Contacts
O’Grady61 Evaluation of the Xpert MTB/RIF assay at a tertiary
care referral hospital in a setting where
tuberculosis and HIV infection are highly endemic
Clinical Infect Dis Zambia 2012 937 recruited suspects,
881 produced enough
sputum
Okumu62 Comparison of performance between Ziehl Neelsen
(ZN) microscopy and the Xpert MTB/RIF assay in
detection of M. tuberculosis in sputum at KEMRI/
CDC TB lab
Conference
abstract
Kenya 2012 262 specimen, 34 HIV-positive patients,
screened for TB
Ozkutuk63 [Evaluation of the Xpert MTB/RIF assay for the
diagnosis of pulmonary and extra-pulmonary
tuberculosis in an intermediate-prevalence
setting]
Mikrobiyoloji Bult Turkey 2014 2639 specimen, 1611
pulmonary
Patients tested for TB
Park64 Comparison of the Xpert MTB/RIF and Cobas
TaqMan MTB assays for detection of
Mycobacterium tuberculosis in respiratory
specimens
J Clin Microbiol Korea 2013 320 consecutive respiratory
specimens
Patients tested for TB
Pimkina65 The XpertW MTB/RIF assay in routine diagnosis of
pulmonary tuberculosis: a multicentre study in
Lithuania
Respiratory
Medicine
Lithuania 2015 833 respiratory samples Persons tested for
tuberculosis
Pinto66 Evaluation of a point-of-care molecular test for M.
tuberculosis detection in an emergency setting
Conference
abstract
Portugal 2012 64 respiratory specimens Patients tested for TB
Porcel67 XpertW MTB/RIF in pleural fluid for the diagnosis of
tuberculosis
Int J Tuberc Lung
Dis
Spain 2013 67 patients Patients tested for TB
Scott68 Dried culture spots for Xpert MTB/RIF external
quality assessment: results of a phase 1 pilot study
in South Africa
J Clin Microbiol South Africa 2011 274 specimens Patients tested for TB
Scott69 Comparison of Xpert MTB/RIF with other nucleic
acid technologies for diagnosing pulmonary
tuberculosis in a high HIV prevalence setting: a
prospective study
PLOS Med South Africa 2011 311 specimens Patients tested for TB
Iram70 Rapid diagnosis of tuberculosis using Xpert MTB/RIF
assay - report from a developing country
Pak J Med Sci Pakistan 2015 205 persons of pulmonary TB Persons tested for TB
Shah71 Xpert MTB/RIF under routine conditions in
diagnosing pulmonary tuberculosis: a study in
two hospitals in Pakistan
Public Health
Action
Pakistan 2013 121 pulmonary TB 606 suspects
Shah72 Comparative performance of urinary
lipoarabinomannan assays and Xpert MTB/RIF in
HIV-infected individuals
AIDS US 2014 103 culture-confirmed TB TB patients
Sharma73 Evaluating the diagnostic accuracy of Xpert MTB/RIF
assay in pulmonary tuberculosis
PLOS ONE India 2015 1439 respiratory samples Persons tested for TB
Siracuse74 GeneXpert MTB/RIF performance evaluation in
respiratory specimens in Ecuador
Conference
abstract
Ecuador 2015 1602 sputum samples Persons tested for TB
Sohn75 Xpert MTB/RIF testing in a low tuberculosis
incidence, high-resource setting: limitations in
accuracy and clinical impact
Clin Infect Dis Canada 2014 502 consecutive patients Patients tested for TB
Teo76 Comparison of two nucleic acid amplification
assays, the Xpert MTB/RIF assay and the amplified
Mycobacterium tuberculosis Direct assay, for
detection of Mycobacterium tuberculosis in
respiratory and non-respiratory specimens
J Clin Microbiol Singapore 2011 162 respiratory specimens Patients tested for TB
Theron77 Evaluation of the Xpert MTB/RIF assay for the
diagnosis of pulmonary tuberculosis in a high HIV
prevalence setting
Am J Respir Crit
Care Med
South Africa 2012 496 patients Patients tested for TB
Theron78 Feasibility, accuracy, and clinical effect of point-of-
care Xpert MTB/RIF testing for tuberculosis in
primary-care settings in Africa: a multicentre,
randomised, controlled trial
Lancet Multisite 2014 744 patients in Xpert group,
182 culture-positive
Patients tested for TB
Tura79 Assessment of laboratory accuracy measures of the
GeneXpert system for the detection of
Mycobacterium tuberculosis (Mtb) in a Philippine
tertiary hospital from October 2014 to February
2015
Conference
abstract
The Philippines 2015 140 clinical samples Persons tested for TB
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Table A.2 (continued)
Study data Xpert sensitivity and specificity
Comments
Inclusion criteria for this systematic review
HIV
%
Sensitivity
(vs. culture)
%
Smearþ
% Smear
Specificity
(vs. culture)
Culture
analysed
Smear
analysed
Xpert
analysed
CT values
reported or
analysed
Median time
to culture
positivity
NR 90 NR 65 100 Yes Yes Yes No No
NR NR 100 0.6 100 Yes Yes Yes No No
NR 100 NR NR NR Sensitivity for RMPresistance
98.2%, specificity 97%
Yes Yes Yes No No
NR 99.8 NR NR 94.1 Yes Yes Yes No No
NR 96.9 NR NR NR NR Yes Yes Yes NR NR
NR 81.1 96.4 71.4 NR Yes Yes Yes No No
NR 92 NR NR NR Article in Russian Yes Yes Yes No No
100 (95%CI
47.81–100.0)
NR NR NR Yes Yes Yes No No
70.9 86.1 NR NR 95 Yes Yes Yes No Yes
NR NR NR NR NR Author was contacted to
see whether culture was
performed, but no
response
Unclear Yes Yes No No
NR 80.8 NR NR 84.9 Article in Turkish Yes Yes Yes No No
NR 67.9 67 69 100 NR Yes Yes Yes No No
NR 93.7 97.8 82.5 91.7 NR Yes Yes Yes NR NR
NR 91 NR NR 100 NR Yes Yes Yes No No
NR 15 100 Yes Yes Yes No No
NR NR NR NR NR On dried culture spots Yes Yes Yes No No
70 86 (95%CI 76–93) NR NR NR Yes Yes Yes No No
NR NR NR NR NR Full-text not accessible,
diagnostic accuracy not
calculable
Yes Yes Yes NR NR
NR NR NR NR NR Yes Yes Yes No No
NR 76 NR NR 97 Yes Yes Yes No No
NR 95.7 77.7 99.3 Yes Yes Yes NR NR
NR NR 92.7 NR NR Yes Yes Yes NR NR
2.4 46 (95%CI 26–67) 86 (95%CI 42–
100)
28 (95%CI 10–56) 100 Yes Yes Yes No Yes
NR 90.1 NR NR 89 Yes Yes Yes No No
NR NR 89/94 (95) (95%CI
88–98)
12/22 (55) (95%CI
35–73)
NR Yes Yes Yes No No
NR 83 NR NR 95 Yes Yes Yes No No
NR 74.2 NR NR NR Yes Yes Yes NR NR
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Table A.2 (continued)
Study data
Author,
reference Study title Journal Country Year
Samples/patients
n
Study
population
Williamson80 An evaluation of the Xpert MTB/RIF assay and
detection of false-positive rifampicin resistance in
Mycobacterium tuberculosis
Diagn Microbiol
Infect Dis
New Zealand 2012 169 specimen Patients tested for TB
Yoon81 Impact of Xpert MTB/RIF testing on tuberculosis
management and outcomes in hospitalized
patients in Uganda
Uganda 2012 477 patients, baseline 287
implementation 190
Patients tested for TB
Zeka82 Evaluation of the GeneXpert MTB/RIF assay for rapid
diagnosis of tuberculosis and detection of
rifampin resistance in pulmonary and extra-
pulmonary specimens
J Clin Microbiol Turkey 2011 253 pulmonary samples 110 patients, 89 culture-
positive, 21 culture-
negative)
Alnimr83 Potential of two nucleic acid amplification assays for
quantifying mycobacterial load in respiratory and
non-respiratory specimens: a prospective study
Diagn Microbiol
Infect Dis
Saudi Arabia 2014 714 samples, 44 culture
positive
Patients tested for TB
Blakemore84 A multisite assessment of the quantitative
capabilities of the Xpert MTB/RIF assay
Am J Respir Crit
Care Med
Multisite 2011 2008 samples TB patients
Friedrich85 Suitability of Xpert MTB/RIF and genotype
MTBDRplus for patient selection for a tuberculosis
clinical trial
J Clin Microbiol South Africa 2011 120 smear positive
tuberculosis patients with
one sample
TB patients
Friedrich86 Assessment of the sensitivity and specificity of Xpert
MTB/RIF assay as an early sputum biomarker of
response to tuberculosis treatment
Lancet Respir Med South Africa,
Tanzania
2013 2741 samples from 221
patients
221 patients with smear
positive tuberculosis
Hanrahan87 Xpert MTB/RIF as a measure of sputum bacillary
burden. Variation by HIV status and
immunosuppression
Am J Respir Crit
Care Med
South Africa 2013 2406 sputum samples, 406
culture positive
Patients tested for TB
Nikolayevskyy88 Utility of propidium monoazide viability assay as a
biomarker for a tuberculosis disease
Tuberculosis Russia, Lithuania,
Latvia
2014 1937 samples of 310 patients Patients tested for TB
Rachow89 Rapid and accurate detection of Mycobacterium
tuberculosis in sputum samples by Cepheid Xpert
MTB/RIF assay—a clinical validation study
PLOS ONE Tanzania 2011 292 adults Patients tested for TB
Theron90 The use of an automated quantitative polymerase
chain reaction (Xpert MTB/RIF) to predict the
sputum smear status of tuberculosis patients
Clin Infect Dis South Africa 2012 496; 141 culture-confirmed Patients tested for TB
Theron91 Accuracy and impact of Xpert MTB/RIF for the
diagnosis of smear-negative or sputum-scarce
tuberculosis using bronchoalveolar lavage fluid
Thorax South Africa 2013 160 patients Patients tested for TB
Theron92 Determinants of PCR performance (Xpert MTB/RIF),
including bacterial load and inhibition, for TB
diagnosis using specimens from different body
compartments
Nature Sci Rep South Africa 2014 865 patients, 172 culture-
confirmed samples
Patients tested for TB
CT ¼ threshold concentration; HIV ¼ human immunodeficiency virus; þ¼ positive; ¼ negative; NR ¼ not reported; TB ¼ tuberculosis; RMP ¼ rifampicin; CI ¼
confidence interval; NTM¼ non-tuberculous mycobacteria; BAL¼ bronchoalveolar lavage.
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Table A.2 (continued)
Study data Xpert sensitivity and specificity
Comments
Inclusion criteria for this systematic review
HIV
%
Sensitivity
(vs. culture)
%
Smearþ
% Smear
Specificity
(vs. culture)
Culture
analysed
Smear
analysed
Xpert
analysed
CT values
reported or
analysed
Median time
to culture
positivity
NR 100 NR NR 100 Yes Yes Yes No No
NR 187/237 (79)
(95%CI 73–84)
NR 34/81 (42) (95%CI
31–54)
190/199 (96)
(95%CI 92–98)
Yes Yes Yes No No
NR 83 1 69 100 Yes Yes Yes No No
NR NR NR NR NR Yes Yes Yes Yes Yes
NR NR NR NR NR 27.7 CT cut-off predicted
smear-positive
Yes Yes Yes Yes Yes
NR 92.9 NR NR NR correlation found between
CT, time to positivity and
microscopy smear grade
Yes Yes Yes Yes Yes
3% Cape Town,
18% Mbeya
97% NR NR 48.6 Yes Yes Yes Yes No
60 NR NR NR NR Yes Yes Yes Yes Yes
2–15 97.5 NR NR 70.8 Yes Yes Yes Yes Yes
60 88.4 (95%CI78.4–
94.9)
99 (95%CI 94.7–
100.0)
97.8 (95%CI
88.2–99.9)
Yes Yes Yes Yes Yes
30 NR NR NR NR Yes Yes Yes yes yes
35 93 NR NR NR Yes Yes Yes Yes Yes
NR NR NR NR NR Uses data from other
Theron studies
Yes Yes Yes Yes Yes
Xpert CT values to predict smear status in TB ix
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R E S U M E
CONT EX T E : L’Xpertw MTB/RIF est le test mole´culaire
le plus utilise´ pour le diagnostic rapide de la tuberculose
(TB). Le nombre de cycles de re´action par le polyme´rase
en chaıˆne apre`s lesquels un produit de´tectable est ge´ne´re´
(valeur cycle seuil, CT) est corre´le´ a` la charge bacillaire.
OB J E C T I F : Explorer l’association entre valeurs de CT
de l’Xpert et statut du frottis graˆce a` une revue
syste´matique et a` une me´ta-analyse au niveau individuel.
S CH E´MA : Les e´tudes consacre´es a` l’association entre
valeurs de CT et statut du frottis ont e´te´ incluses dans une
revue syste´matique descriptive. On a demande´ aux
auteurs des e´tudes des donne´es individuelles, incluant
les re´sultats du frottis, de la culture et de l’Xpert, et les
courbes de la fonction d’efficacite´ du re´cepteur (ROC)
ont e´te´ calcule´es.
R E´ S U LTAT S : Sur les 918 citations, 10 ont e´te´ incluses
dans la revue descriptive syste´matique ; 15 ensembles de
donne´es e´manant d’e´tudes potentiellement pertinentes
pour la me´ta-analyse des donne´es individuelles ont
fourni des donne´es pour 7511 e´chantillons et 4447
patients ; 1212 patients ont eu des re´sultats d’Xpert
positifs pour au moins un e´chantillon respiratoire (1859
e´chantillons au total). L’analyse ROC a re´ve´le´ un surface
situe´e sous la courbe de 0,85 (IC95% 0,82–0,87). Une
valeur CT seuil de 27,7 et 31,8 a abouti a` une sensibilite´
de 85% (IC95% 83–87) et de 95% (IC95% 94–96)
respectivement et a` une spe´cificite´ de 67% (IC95% 66–
77) et de 35% (IC95% 30–41) respectivement pour les
e´chantillons a` frottis positif.
CONC LU S I ON : Les valeurs CT de l’Xpert et le statut du
frottis ont e´te´ fortement associe´es. Cependant, la
pre´cision diagnostique a` un seuil de valeur CT de 27,7
ou 31,8 ne remplacerait pas la microscopie de frottis. Il
reste a` voir comment les valeurs CT peuvent eˆtre
compare´es a` la microscopie de frottis dans la
pre´diction de la contagiosite´.
R E S UM E N
MARCO DE R E F E R ENC I A: La prueba Xpertw MTB/RIF
es el me´todo molecular de diagno´stico ra´pido de la
tuberculosis (TB) ma´s utilizado. El nu´mero de ciclos de
la reaccio´n en cadena de la polimerasa a partir del cual se
genera un producto detectable (ciclo umbral, CT) se
correlaciona con la cantidad de micobacterias en la
muestra.
OB J E T I VO: Investigar la asociacio´n entre el valor del CT
de la prueba Xpert y la calificacio´n de la baciloscopia,
mediante una revisio´n sistema´tica y el metana´lisis de
datos a escala individual.
M E´ TODO: En una revisio´n sistema´tica descriptiva se
incluyeron estudios sobre la asociacio´n de los valores del
CT y la calificacio´n de la baciloscopia. Se solicito´ a los
autores de los estudios que comportaban resultados de
baciloscopias, cultivos y pruebas Xpert que
comunicaran los datos a nivel individual y se
calcularon la curvas de eficacia diagno´stica.
R E SU LTADOS: En la revisio´n sistema´tica descriptiva se
incluyeron 10 de las 918 citas de artı´culos. Se obtuvieron
los datos individuales de 15 conjuntos de datos de
estudios que podı´an ser pertinentes en el metana´lisis de
datos individuales (7511 muestras de 4447 pacientes).
En 1212 pacientes se observaron resultados positivos de
la prueba Xpert de por lo menos una muestra
respiratoria (1859 muestras en total). El ana´lisis de la
eficacia diagno´stica revelo´ un a´rea bajo la curva de 0,85
(IC95% 0,82 a 0,87). Al adoptar valores lı´mites del CT
de 27,7 y de 31,8 se obtuvieron respectivamente
sensibilidades de 85% (IC95% de 83 a 87) y 95%
(IC95% de 94 a 96) y especificidades de 67% (IC95% de
66 a 77) y 35% (IC95% de 30 a 41) para las muestras
con baciloscopia positiva.
CONC LU S I O´ N: El valor del CT de la prueba Xpert y la
clasificacio´n de la baciloscopia exhibieron una fuerte
correlacio´n. Sin embargo, la precisio´n diagno´stica de la
prueba cuando se define un valor lı´mite del CT de 27,7 o
de 31,8 no remplazarı´a la baciloscopia. Queda por
discernir cua´l de los dos datos, el valor del CT de la
prueba Xpert o la baciloscopia, pronosticarı´a mejor la
contagiosidad.
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